SUMMARY The course of 76 pregnancies is reported in 51 women who became pregnant after replacement of one or more heart valves. Age at conception ranged from 17 to 39 years (mean 25). There have been 71 deliveries and five women are still pregnant at the time of writing. In the 71 pregnancies, oral anticoagulants were given during 53, heparin during five, and no anticoagulants during 13. Fetal complications consisted of 12 spontaneous abortions (eight in pregnancies in which oral anticoagulants were given, three in which heparin was given, and one in which no anticoagulants were given), of 12 premature deliveries with seven stillbirths (three on oral anticoagulants and four without anticoagulants), and there were three neonatal deaths (in all three instances oral anticoagulants had been given during pregnancy). The maternal complications were as follows. Two women with mitral valve prostheses on heparin had thromboembolic episodes. Four women on oral anticoagulants died and 11 developed haemorrhage or systemic embolism. Two of the deaths were caused by bacterial endocarditis, one was the result of obstruction of a mitral valve prosthesis, and one was due to haemorrhage. One patient developed pulmonary oedema during delivery which rapidly resolved. Seven patients had uterine bleeding after delivery (three of them were on heparin and one was on an antiplatelet agent). 
In 1966 DiSaia reported the first pregnancy and delivery in a patient with a Starr-Edwards valve prosthesis.' Since then there have been numerous case reports and a few small series. A review of one of the largest series, comprising 25 women and 28 pregnancies, appeared in 1976. 2 Complications of pregnancy are mainly related to the continuous use of anticoagulants. The increased coagulability normally seen in pregnancy increases the requirement for anticoagulants in women with heart valve prostheses. We report our experience of a large series (51 women, 76 pregnancies) and describe the difficulties associated with the management of pregnancy after heart valve replacement.
Patients and methods
There have been 76 pregnancies in 51 of 392 women aged <40 years with prosthetic heart valves who have been followed by us at this hospital. There Ben Ismail, Abid, Trabelsi., Taktak, Fekih Cardiac valve prostheses, anticoagulation, and pregnancy obstruction of a Starr-Edwards mitral valve prosthesis a few days after delivery in a patient who was on oral anticoagulants until the beginning of the ninth month of pregnancy and was then on heparin. Heparin was stopped at the start of labour and restarted six hours after delivery. The fourth death occurred in the seventh month of pregnancy in a woman who had a severe haemorrhagic episode due to an excessive dose of anticoagulants; the fetus died in utero.
At delivery pulmonary oedema developed in one patient, this responded rapidly to treatment; seven patients presented with uterine bleeding after delivery: three of them were on heparin and one was on an antiplatelet agent.
Discussion
It is difficult to predict the outcome of pregnancy in women with artificial heart valves. Cardiac output increases by up to 50% in pregnancy; this is normally achieved by an increase in stroke volume rather than by an increase in heart rate.3 Like others,245 we found that pregnancy in women with heart valve prostheses, even those with triple valve replacement, is usually well tolerated when the heart has a good ventricular reserve, is in sinus rhythm, and has properly functioning valves.6
Increases in the concentrations of coagulation factors4 and a reduction in fibrinolysis in pregnancy7 add to the risk of thromboembolism associated with the presence of a prosthetic heart valve. The clinical manifestations of thromboembolism associated with artificial heart valves in pregnant women do not differ from those seen in non-pregnant women. 8 The most serious complication that we saw was prosthetic valve thrombosis in three patients, which was fatal in two, despite reoperation in one It is widely believed that discontinuation of anticoagulant treatment increases the risk of systemic embolisation in the mother; on the other hand, their use during early pregnancy, near term and at delivery has been reported to be associated with an increased incidence of fetal malformation, stillbirths, and neonatal deaths from haemorrhage. Oral anticoagulants have small molecules that can cross the placenta and they are known to be teratogenic. In 1949, studies in rabbits by Kraus et al indicated that the use of coumarin during pregnancy may endanger the fetus.10 In 1966 DiSaia reported on the first pregnancy after implantation of a cardiac valve prosthesis; this fullterm infant, born to a mother who had received coumarin treatment in early pregnancy, had severe nasal hypoplasia and bilateral optic atrophy.' Shaul and Hall summarised the abnormalities seen in 11 patients who had been exposed prenatally to warfarin derivatives."l The most constant features were nasal hypoplasia and stippled epiphyses. " Hall et al reviewed 24 cases in 1980 and confirmed these findings.'2 Other abnormalities included optic atrophy, cataracts, mental retardation, and flexion contractures.
The critical period for teratogenesis is the sixth to the ninth week of gestation, and this may explain why we did not see malformations in our series. Our Ben Ismail, Abid, Trabelsi, Taktak, Fekih patients had not usually been treated with anticoagulants in the first trimester. Fetal loss due to abortion, stillbirth, or premature delivery is another complication of anticoagulant treatment. We and others have established that there is unquestionably an increased risk of fetal loss in pregnant women treated with anticoagulants. This risk is especially high when oral anticoagulants are administered from early pregnancy until term and when the dose of anticoagulant is sufficient to depress the prothrombin concentration even for only two days.9"3"4 In a large review in 1975 Harrisson and Roschke noted that in 55 pregnancies in which the mother had been receiving an anticoagulant (usually warfarin) throughout pregnancy, fetal wastage was 29%, whereas there was no fetal loss in 14 pregnancies in which no anticoagulants were used. 15 Lutz et al reported spontaneous fetal wastage of 56% in pregnancies in which coumarin anticoagulants had been given in the first trimester.16
Ibarra-Perez et al reported nine spontaneous abortions in 25 pregnancies in which oral anticoagulants were used virtually throughout pregnancy.2 In 1979 we reviewed 133 published cases in which there was 30% fetal wastage (21 abortions and 18 stillbirths); of the 39 fetal losses, only one occurred in a patient who was not on anticoagulants and in 10 women there was an obviously reduced coagulability; 12 of the 18 perinatal deaths occurred when oral anticoagulants were taken until term. 8 Hirsh et al stressed the importance of discontinuing oral anticoagulants before term to allow their elimination by the fetus and the restoration of normal prothrombin time.'7 There is evidence that abortions, stillbirths, and early deaths are caused by placental detachment or internal or cerebral haemorrhage; bleeding may be due to the hypocoagulable state in the fetus,8 which is very sensitive to anticoagulants because of the immaturity of the liver. Thus the fetal prothrombin time may be considerably prolonged even when that of the mother is normal.'8 To avoid bleeding complications in the fetus, maternal prothrombin times should be maintained in the low normal range. There is evidence that heparin does not cross the placenta and therefore it is unlikely to be teratogenic.18 Administration and monitoring of treatment are difficult, however, and fetal and maternal haemorrhage may occur. The maternal complication rate was high in a series of 135 cases. Fourteen patients (10%) had a haemorrhage and three (2%) of them died.'2 Thirty three per cent of deliveries were premature or stillbirths. Heparin may be substituted for oral anticoagulants in pregnant women with heart valve prostheses, but this change can only be purposefully instituted when the pregnancy is recognised early and before the most vulnerable period for the fetus.
Conclusions
The risk of heart failure during pregnancy in women with heart valve prostheses is usually not great when bed rest and appropriate medical treatment are feasible; however, patients in functional class III and IV of the New York Heart Association classification with large left atrium and atrial fibrillation should be advised against pregnancy. Such patients are, however, not often encountered because most of them will have had surgical treatment before pregnancy in order to prevent deterioration of cardiac function.
The maternal risk of thromboembolism is high and it is not always prevented by anticoagulants. We found that heparin was less effective than oral anticoagulants and we did not find any teratogenic effects associated with oral anticoagulants. So, although many prefer to use heparin in the first trimester of pregnancy, we do not think that this is justified, even when pregnancy is diagnosed sufficiently early or is planned for. We do, however, recommend the use of heparin at the end of pregnancy to reduce the risk of haemorrhage during labour and delivery. Mothers on anticoagulants are often advised against breast feeding; however, there is evidence that those on warfarin may safely breast feed their infants. 19 Because of the difficulties encountered in the management of pregnant women with artificial heart valves, some workers strongly recommend the use of bioprosthetic heart valves in women of child bearing age; but we believe that this attempt to reduce the risk of rapid valve failure is justified only in patients in sinus rhythm who are > 25 years old.
